“…We evaluated all patients with CHD that were admitted to our institution for initiation of D for the treatment of AT. Patients were classified as having persistent vs. paroxysmal AF, AFL, or atrial tachycardia according to electrocardiographic and clinical criteria . All ATs lasting more than 7 days were classified as persistent, regardless of the suspected mechanism.…”
Section: Methodsmentioning
confidence: 99%
“…Patients were classified as having persistent vs. paroxysmal AF, AFL, or atrial tachycardia according to electrocardiographic and clinical criteria. 12,16 All ATs lasting more than 7 days were classified as persistent, regardless of the suspected mechanism. D starting dose was chosen and adjusted according the individual's creatinine clearance and corrected QT interval (QTc), following the guidelines established for the DIAMOND trial.…”
D should be considered a pharmacologic alternative when adult patients with CHD develop AT. D does not depress conduction, sinus node, or ventricular function but needs close monitoring for potential ventricular pro-arrhythmia.
“…We evaluated all patients with CHD that were admitted to our institution for initiation of D for the treatment of AT. Patients were classified as having persistent vs. paroxysmal AF, AFL, or atrial tachycardia according to electrocardiographic and clinical criteria . All ATs lasting more than 7 days were classified as persistent, regardless of the suspected mechanism.…”
Section: Methodsmentioning
confidence: 99%
“…Patients were classified as having persistent vs. paroxysmal AF, AFL, or atrial tachycardia according to electrocardiographic and clinical criteria. 12,16 All ATs lasting more than 7 days were classified as persistent, regardless of the suspected mechanism. D starting dose was chosen and adjusted according the individual's creatinine clearance and corrected QT interval (QTc), following the guidelines established for the DIAMOND trial.…”
D should be considered a pharmacologic alternative when adult patients with CHD develop AT. D does not depress conduction, sinus node, or ventricular function but needs close monitoring for potential ventricular pro-arrhythmia.
“…Recent advanced 3-D electroanatomical mapping systems (eg, CARTO and the non-contact mapping systems) are very helpful in detecting the magnitude and extent of the underlying myocardial damage by creating a substrate map, clarifying the tachycardia mechanism and circuit by creating activation and propagation maps, and determining the optimal ablation site. [4][5][6][7][8][9] This new method may improve the success rate of electrophysiologically guided and anatomically guided catheter ablation of unusual, focal and macro-reentrant tachycardias, as in this case.…”
Section: Images In Cardiovascular Medicine Unusual Macro-reentrant Aflmentioning
“…Aiba and colleagues used body surface mapping (BSM) to differentiate these tachycardias before doing a catheter ablation. 6 They demonstrated that BSM combined with the signal-averaged ECG could characterize atrial reentrant tachycardias and differentiate between cavotricuspid isthmus dependent atrial flutter, incisional reentrant tachycardia and double-loop reentry. The determination of the type of atrial tachycardia before the catheter ablation would be beneficial for patients and helpful for physicians.…”
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.